EP1562920B1 - 3-arylthio-3-thiazolyl-alkylamines anti-inflammatoires - Google Patents

3-arylthio-3-thiazolyl-alkylamines anti-inflammatoires Download PDF

Info

Publication number
EP1562920B1
EP1562920B1 EP03770201A EP03770201A EP1562920B1 EP 1562920 B1 EP1562920 B1 EP 1562920B1 EP 03770201 A EP03770201 A EP 03770201A EP 03770201 A EP03770201 A EP 03770201A EP 1562920 B1 EP1562920 B1 EP 1562920B1
Authority
EP
European Patent Office
Prior art keywords
formula
compound
pharmaceutically acceptable
acceptable salt
thiazolyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP03770201A
Other languages
German (de)
English (en)
Other versions
EP1562920A1 (fr
Inventor
Jeffrey AstraZeneca R & D Charnwood STONEHOUSE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of EP1562920A1 publication Critical patent/EP1562920A1/fr
Application granted granted Critical
Publication of EP1562920B1 publication Critical patent/EP1562920B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms

Definitions

  • the present invention relates to novel arylthiazolylthioalkylamine derivatives, processes for their preparation, compositions containing them and their use in therapy.
  • Nitric oxide is produced in mammalian cells from L-arginine by the action of specific nitric oxide synthases (NOSs). These enzymes fall into two distinct classes - constitutive NOS (cNOS) and inducible NOS (iNOS). At the present time, two constitutive NOSs and one inducible NOS have been identified. Of the constitutive NOSs, an endothelial enzyme (ecNOS) is involved with smooth muscle relaxation and the regulation of blood pressure and blood flow, whereas the neuronal enzyme (ncNOS) serves as a neurotransmitter and appears to be involved in the regulation of various biological functions such as cerebral ischaemia. Inducible NOS has been particularly implicated in the pathogenesis of inflammatory diseases. Regulation of these enzymes should therefore offer considerable potential in the treatment of a wide variety of disease states (J. E. Macdonald, Ann . Rep. Med. Chem ., 1996, 31, 221 - 230).
  • ecNOS endothelial enzyme
  • Patent application WO 02/090332 discloses certain arylheteroalkylamine derivatives that are useful as NOS inhibitors. It has now been found that certain compounds that are within the generic scope of this application, but which are not specifically exemplified therein, possess surprisingly advantageous properties. These compounds are the subject of the present application.
  • Y represents CN or halogen.
  • X and R 1 independently represent H, halogen or CF 3 .
  • the compounds of formula (I) and their pharmaceutically acceptable salts have the advantage that they are inhibitors of the enzyme nitric oxide synthase (NOS).
  • the compounds of formula (I) and their pharmaceutically acceptable salts have the advantage that they are inhibitors of the inducible isoform of the enzyme nitric oxide synthase (iNOS).
  • the invention further provides a process for the preparation of compounds of formula (I) or a pharmaceutically acceptable salt, enantiomer or racemate thereof.
  • Another aspect of the invention provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament, for the treatment or prophylaxis of diseases or conditions in which inhibition of nitric oxide synthase activity is beneficial.
  • a more particular aspect of the invention provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament, for the treatment or prophylaxis of inflammatory disease.
  • a method of treating, or reducing the risk of, diseases or conditions in which inhibition of nitric oxide synthase activity is beneficial which comprises administering to a person suffering from or at risk of, said disease or condition, a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.
  • a method of treating, or reducing the risk of, inflammatory disease in a person suffering from or at risk of, said disease comprises administering to the person a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.
  • the compounds of the present invention may also be used advantageously in combination with a second pharmaceutically active substance; particularly in combination with a cyclooxygenase inhibitor; more particularly in combination with a selective inhibitor of the inducible isoform of cyclooxygenase (COX-2).
  • a second pharmaceutically active substance particularly in combination with a cyclooxygenase inhibitor; more particularly in combination with a selective inhibitor of the inducible isoform of cyclooxygenase (COX-2).
  • COX-2 selective inhibitor of the inducible isoform of cyclooxygenase
  • a method of treating, or reducing the risk of, inflammation, inflammatory disease and inflammatory related disorders in a person suffering from or at risk of, said disease or condition comprises administering to the person a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof in combination with a COX-2 inhibitor.
  • Particular compounds of the invention include:
  • C1 to 4 alkyl denotes a straight or branched chain alkyl group having from 1 to 4 carbon atoms. Examples of such groups include methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl and t-butyl.
  • C1 to 4 alkoxy denotes a straight or branched chain alkoxy group having from 1 to 4 carbon atoms. Examples of such groups include methoxy, ethoxy, n-propoxy, i-propoxy and t-butoxy.
  • halogen referred to herein denotes fluoro, chloro, bromo and iodo.
  • Examples of a "C1 to 4 alkyl or C1 to 4 alkoxy optionally further substituted by one or more fluorine atoms" include CH 2 F, CHF 2 , CF 3 , CF 3 CF 2 , CF 3 CH 2 , CH 2 FCH 2 , CH 3 CF 2 , CF 3 CH 2 CH 2 , OCF 3 and OCH 2 CF 3 .
  • the reaction is performed by treating a nucleophile of formula (III) with an electrophile of formula (II) in an inert solvent.
  • Suitable leaving groups L 1 include sulphonates and halides, particularly fluoride or chloride.
  • the reaction is generally performed in the presence of a non-nucleophilic base such as sodium hydride or caesium carbonate.
  • Suitable organic solvents are those such as N,N-dimethylformamide, N-methyl-2-pyrrolidinone, tetrahydrofuran and dimethylsulfoxide.
  • the reaction is generally conducted at a temperature between 0 °C and the boiling point of the solvent.
  • the reactants (IV) and (V) are coupled together in a suitable inert solvent such as tetrahydrofuran using, for example, Mitsunobu conditions.
  • a suitable inert solvent such as tetrahydrofuran
  • the reactants are treated with a phosphine derivative and an azo derivative at a suitable temperature, generally between 0 °C and the boiling point of the solvent.
  • Suitable phosphine derivatives include triphenylphosphine and tributylphosphine.
  • Suitable azo derivatives include diethyl azodicarboxylate, diisopropyl azodicarboxylate and 1,1'-(azodicarbonyl)dipiperidine.
  • Suitable leaving groups L 2 include hydroxy.
  • the reaction is performed by treating a nucleophile of formula (IV) with an electrophile of formula (V) in an inert solvent.
  • Suitable leaving groups L 2 include sulphonates and halides, particularly chloride or bromide.
  • the reaction is generally performed in the presence of a non-nucleophilic base such as sodium hydride or caesium carbonate.
  • Suitable organic solvents are those such as N,N-dimethylformamide, N-methyl-2-pyrrolidinone, tetrahydrofuran and dimethylsulfoxide.
  • the reaction is generally conducted at a temperature between 0 °C and the boiling point of the solvent.
  • amine groups are protected as carbamate derivatives, for example, as t-butyloxycarbamates.
  • the amine and hydroxyl groups of compounds of formula (I) are protected simultaneously as a cyclic hemi-aminal as in formula (VI).
  • the present invention includes compounds of formula (I) in the form of salts, in particular acid addition salts.
  • Suitable salts include those formed with both organic and inorganic acids.
  • Such acid addition salts will normally be pharmaceutically acceptable although salts of non-pharmaceutically acceptable acids may be of utility in the preparation and purification of the compound in question.
  • preferred salts include those formed from hydrochloric, hydrobromic, sulphuric, phosphoric, citric, tartaric, lactic, pyruvic, acetic, succinic, fumaric, maleic, methanesulphonic and benzenesulphonic acids.
  • Salts of compounds of formula (I) may be formed by reacting the free base, or a salt, enantiomer or racemate thereof, with one or more equivalents of the appropriate acid.
  • the reaction may be carried out in a solvent or medium in which the salt is insoluble or in a solvent in which the salt is soluble, for example, water, dioxane, ethanol, tetrahydrofuran or diethyl ether, or a mixture of solvents, which may be removed in vacuo or by freeze drying.
  • the reaction may also be a metathetical process or it may be carried out on an ion exchange resin.
  • the compounds of the invention and intermediates thereto may be isolated from their reaction mixtures and, if necessary further purified, by using standard techniques.
  • the compounds of formula I may exist in enantiomeric forms. Therefore, all enantiomers, diastereomers, racemates and mixtures thereof are included within the scope of the invention.
  • the various optical isomers may be isolated by separation of a racemic mixture of the compounds using conventional techniques, for example, fractional crystallisation, or HPLC.
  • Intermediate compounds may also exist in enantiomeric forms and may be used as purified enantiomers, diastereomers, racemates or mixtures.
  • the compounds of formula (I) and their pharmaceutically acceptable salts are useful because they possess pharmacological activity in animals.
  • the compounds are active as inhibitors of the enzyme nitric oxide synthase. More particularly, they are inhibitors of the inducible isoform of the enzyme nitric oxide synthase and as such are predicted to be useful in therapy, for example, as anti-inflammatory agents. They may also have utility as inhibitors of the neuronal isoform of the enzyme nitric oxide synthase.
  • the compounds and their pharmaceutically acceptable salts are indicated for use in the treatment or prophylaxis of diseases or conditions in which synthesis or oversynthesis of nitric oxide synthase forms a contributory part.
  • the compounds are indicated for use in the treatment of inflammatory conditions in mammals including man.
  • the compounds will also be useful in the treatment and alleviation of acute pain or persistent inflammatory pain or neuropathic pain or pain of a central origin.
  • the compounds of formula (I) and their pharmaceutically acceptable salts may also be useful in the treatment or prophylaxis of diseases or conditions in addition to those mentioned above.
  • the compounds may be useful in the treatment of atherosclerosis, cystic fibrosis, hypotension associated with septic and/or toxic shock, in the treatment of dysfunction of the immune system, as an adjuvant to short-term immunosuppression in organ transplant therapy, in the control of onset of diabetes, in the maintenance of pancreatic function in diabetes, in the treatment of vascular complications associated with diabetes and in co-therapy with cytokines, for example TNF or interleukins.
  • cytokines for example TNF or interleukins.
  • the compounds of formula (I) may also be useful in the treatment of hypoxia, for example in cases of cardiac arrest and stroke, neurodegenerative disorders including nerve degeneration and/or nerve necrosis in disorders such as ischaemia, hypoxia, hypoglycaemia, epilepsy, and in external wounds (such as spinal cord and head injury), hyperbaric oxygen convulsions and toxicity, dementia, for example pre-senile dementia, Alzheimer's disease and AIDS-related dementia, Sydenham's chorea, Parkinson's disease, Tourette's syndrome, Huntington's disease, amyotrophic lateral sclerosis, multiple sclerosis, muscular dystrophy, Korsakoffs disease, imbecility relating to a cerebral vessel disorder, sleeping disorders, schizophrenia, depression, pain, autism, seasonal affective disorder, jet-lag, depression or other symptoms associated with premenstrual syndrome (PMS), anxiety and septic shock.
  • PMS premenstrual syndrome
  • Compounds of formula (I) may also be expected to show activity in the prevention and reversal of drug addiction or tolerance such as tolerance to opiates and diazepines, treatment of drug addiction, treatment of migraine and other vascular headaches, neurogenic inflammation, in the treatment of gastrointestinal motility disorders, cancer and in the induction of labour.
  • drug addiction or tolerance such as tolerance to opiates and diazepines, treatment of drug addiction, treatment of migraine and other vascular headaches, neurogenic inflammation, in the treatment of gastrointestinal motility disorders, cancer and in the induction of labour.
  • Prophylaxis is expected to be particularly relevant to the treatment of persons who have suffered a previous episode of, or are otherwise considered to be at increased risk of, the disease or condition in question.
  • Persons at risk of developing a particular disease or condition generally include those having a family history of the disease or condition, or those who have been identified by genetic testing or screening to be particularly susceptible to developing the disease or condition.
  • the dosage administered will, of course, vary with the compound employed, the mode of administration and the treatment desired. However, in general, satisfactory results are obtained when the compounds are administered at a dosage of the solid form of between 1 mg and 2000 mg per day.
  • the compounds of formula (I), and pharmaceutically acceptable derivatives thereof may be used on their own, or in the form of appropriate pharmaceutical compositions in which the compound or derivative is in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier.
  • Administration may be by, but is not limited to, enteral (including oral, sublingual or rectal), intranasal, inhalation, intravenous, topical or other parenteral routes.
  • enteral including oral, sublingual or rectal
  • intranasal inhalation
  • intravenous topical or other parenteral routes.
  • Conventional procedures for the selection and preparation of suitable pharmaceutical formulations are described in, for example, "Pharmaceuticals - The Science of Dosage Form Designs", M. E. Aulton, Churchill Livingstone, 1988.
  • the pharmaceutical composition preferably comprises less than 80% and more preferably less than 50% of a compound of formula (I), or a pharmaceutically acceptable salt thereof.
  • a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier.
  • the compounds of formula (I), and pharmaceutically acceptable derivatives thereof, may also be advantageously used in combination with a COX inhibitor, more particularly in combination with a COX-2 inhibitor.
  • COX-2 inhibitors are Celecoxib and MK-966.
  • the NOS inhibitor and the COX-2 inhibitor may either be formulated together within the same pharmaceutical composition for administration in a single dosage unit, or each component may be individually formulated such that separate dosages may be administered either simultaneously or sequentially.
  • n -Butyl lithium (2.0M in hexanes, 21.6 ml) was added dropwise to a solution of 2-chlorothiazole (5.4 g) in THF (400 ml) at -78 °C under a nitrogen atmosphere. After 15 minutes a solution of (4 S )-2,2-dimethyl-4-(2-oxoethyl)-3-oxazolidinecarboxylic acid, 1,1-dimethylethyl ester (7.0 g) in THF (140 ml) was added dropwise and the reaction mixture was stirred for a further 60 minutes. The cooling was then removed and the mixture was stirred at room temperature for 60 minutes.
  • Example 1 step (c) The product from Example 1 step (c) (290 mg) was treated with 7M ammonia in methanol (5 ml) and stirred at room temperature for 6 h. The solvent was evaporated, the residue dissolved in dry DMF (5 ml) and treated with 2,5-dichloro-3-pyridinecarbonitrile (112 mg) followed by cesium carbonate (210 mg) under nitrogen. The reaction mixture was stirred for 18 h, poured into brine and ethyl acetate and the organic layer separated, washed with water (2 x), brine and dried (magnesium sulfate).
  • Example 1 step (c) The product from Example 1 step (c) (290 mg) was treated with 2-fluoro-4-chlorobenzonitrile (101 mg) and cesium carbonate (211 mg) according to the procedure of Example 1 step (d) to give the sub-title compound (160 mg) as a viscous oil.
  • Example 2 step (a) The product of Example 2 step (a) was stirred in 4M HCl in dioxane (1 ml) and methanol (1 ml) for 1 h. The reaction mixture was evaporated, azeotroped with diethyl ether (3 x) and dried in vacuo at 40 °C for 2 h to give the title compound (113 mg) as a pale yellow solid. MS APCI + ve m /z 340 ([M+H] + ).
  • Example 1 step (c) The product from Example 1 step (c) (190 mg) was treated with 4-chloro-3-fluorobenzotrifluoride (83 mg) and cesium carbonate (163 mg) according to the procedure of Example 1 step (d) to give the sub-title compound (105 mg) as a viscous oil.
  • Example 3 step (a) was reacted according to the procedure of Example 2 step (b) to give the title compound (58 mg) as a white solid containing the (2S, 4S) diastereomer as a 30% impurity.
  • MS APCI + ve m /z 383 ([M+H] + ).
  • 1 H NMR 300MHz (DMSO-d 6 ) 9.04 (1H, s), 8.15 (2H, br s), 7.86 (1H, d), 7.77-7.69 (2H, m), 7.61 (1H, s), 5.54 (1H, t), 3.63-3.55 (1H, m), 3.13-3.01 (2H, m), 2.34-2.19 (2H, m).
  • Example 1 step (c) The product from Example 1 step (c) (190 mg) was treated with 2-chloro-6-trifluoromethyl-3-pyridinecarbonitrile (86 mg) and cesium carbonate (163 mg) according to the procedure of Example 1 step (d) to give the sub-title compound (117 mg) as a viscous oil.
  • Example 4 step (a) was reacted according to the procedure of Example 2 step (b) to give the title compound (85 mg) as a white solid.
  • 1 H NMR 300MHz (DMSO-d 6 ) 9.04 (1H, s), 8.57 (1H, d), 8.20 (2H, bs), 7.97 (1H, s), 7.89 (1H, d), 5.68 (1H, t), 3.60-3.56 (1H, m), 3.52 (1H, dd), 3.18-3.09 (1H, m), 2.48-2.41 (2H, m).
  • Example 1 step (c) The product from Example 1 step (c) (190 mg) was treated with 5-chloro-2-fluorobenzonitrile (65 mg) and cesium carbonate (163 mg) according to the procedure of Example 1 step (d) to give the sub-title compound (160 mg) as a viscous oil.
  • Example 5 step (a) was reacted according to the procedure of Example 2 step (b) to give the title compound (97 mg) as a pale yellow solid.
  • 1 H NMR 300MHz (DMSO d 6 ) 9.04 (1H, s), 8.27 (2H, br s), 8.04 (1H, d), 7.81 (1H, s), 7.77-7.74 (2H, m), 5.58 (1H, t), 3.57 (1H, dd), 3.51 (1H, dd), 3.07-3.00 (1H, m), 2.27 (2H, t).
  • the activity of compounds of formula (I), or a pharmaceutically acceptable salt thereof, may be screened for nitric oxide synthase inhibiting activity by a procedure based on that of Förstermann et al ., Eur. J. Pharm., 1992, 225 , 161-165.
  • Nitric oxide synthase converts 3 H-L-arginine into 3 H-L-citrulline which can be separated by cation exchange chromatography and quantified by liquid scintillation counting.
  • Enzyme is prepared, after induction, from the cultured murine macrophage cell line J774A-1 (obtained from the laboratories of the Imperial Cancer Research Fund). J774A-1 cells are cultured in Dulbeccos Modified Eagles Medium (DMEM) supplemented with 10% foetal bovine serum, 4 mM L-glutamine and antibiotics (100 units/ml penicillin G, 100 mg/ml streptomycin & 0.25 mg/ml amphotericin B). Cells are routinely grown in 225 cm 3 flasks containing 35 ml medium kept at 37 °C and in a humidified atmosphere containing 5% CO 2 .
  • DMEM Dulbeccos Modified Eagles Medium
  • Nitric oxide synthase is produced by cells in response to interferon-g (IFNg) and lipopolysaccharide (LPS).
  • IFNg interferon-g
  • LPS lipopolysaccharide
  • the medium from confluent culture flasks is removed and replaced with 25 ml (per flask) of fresh medium containing 1 mg/ml LPS and 10 units/ml IFNg.
  • harvesting of cells is accomplished by scraping the cell sheet from the flask surface into the culture medium.
  • Cells are collected by centrifugation (1000 g for 10 minutes) and lysate prepared by adding to the cell pellet a solution containing 50 mM Tris-HCl (pH 7.5 at 20 °C), 10% (v/v) glycerol, 0.1 % (v/v) Triton-X-100, 0.1 mM dithiothreitol and a cocktail of protease inhibitors comprising leupeptin (2 mg/ml), soya bean trypsin inhibitor (10 mg/ml), aprotinin (5 mg/ml) and phenylmethylsulphonyl fluoride (50 mg/ml).
  • protease inhibitors comprising leupeptin (2 mg/ml), soya bean trypsin inhibitor (10 mg/ml), aprotinin (5 mg/ml) and phenylmethylsulphonyl fluoride (50 mg/ml).
  • substrate cocktail 50 mM Tris-HCl (pH 7.5 at 20 °C), 400 ⁇ M NADPH, 20 ⁇ M flavin adenine dinucleotide, 20 ⁇ M flavin mononucleotide, 4 ⁇ M tetrahydrobiopterin, 12 ⁇ M L-arginine and 0.025 mCi L-[ 3 H] arginine
  • substrate cocktail 50 mM Tris-HCl (pH 7.5 at 20 °C), 400 ⁇ M NADPH, 20 ⁇ M flavin adenine dinucleotide, 20 ⁇ M flavin mononucleotide, 4 ⁇ M tetrahydrobiopterin, 12 ⁇ M L-arginine and 0.025 mCi L-[ 3 H] arginine
  • the reaction is started by adding 50 ⁇ l of cell lysate (prepared as above) and after incubation for 1 hour at room temperature is terminated by addition of 50 ⁇ l of an aqueous solution of 3 mM nitroarginine and 21 mM EDTA.
  • Labelled L-citrulline is separated from labelled L-arginine using Dowex AG-50W.
  • 150 ⁇ l of a 25% aqueous slurry of Dowex 50W (Na + form) is added to the assay after which the whole is filtered into 96 well plates.
  • 75 ⁇ l of filtrate is sampled and added to wells of 96 well plates containing solid scintillant. After allowing the samples to dry the L-citrulline is quantified by scintillation counting.
  • basal activity is 300 dpm per 75 ⁇ l sample which is increased to 1900 dpm in the reagent controls.
  • Compound activity is expressed as IC 50 (the concentration of drug substance which gives 50% enzyme inhibition in the assay) and aminoguanidine, which gives an IC 50 (50% inhibitory concentration) of 10 ⁇ M, is tested as a standard to verify the procedure.
  • Compounds are tested at a range of concentrations and from the inhibitions obtained IC 50 values are calculated.
  • Compounds that inhibit the enzyme by at least 25% at 100 ⁇ M are classed as being active and are subjected to at least one retest.
  • Recombinant human NO synthases (iNOS, eNOS & nNOS) were expressed in E . coli and lysates were prepared in Hepes buffer (pH 7.4) containing co-factors (FAD, FMN, H 4 B), protease inhibitors, lysozyme and the detergent, CHAPS. These preparations were used, at suitable dilution, to assess inhibition of the various isoforms. Inhibition of NOS was determined by measuring the formation of L-[ 3 H]citrulline from L-[ 3 H]arginine using an adaptation of the method of Förstermann et al .
  • Enzyme assays were performed in the presence of 3 ⁇ M [ 3 H]arginine, 1 mM NADPH and other co-factors required to support NOS activity (FAD, FMN, H 4 B, calmodulin, Ca 2+ ). Since various NOS inhibitors have been reported to exhibit slow binding kinetics, or to inactivate the enzyme in a time dependent manner, enzyme and inhibitor were pre-incubated for 60 min in the presence of NADPH before addition of arginine to initiate the reaction. Incubations continued for a further 60 min before the assays were quenched and [ 3 H]citrulline separated from unreacted substrate by chromatography on Dowex-50W resin in a 96-well format.
  • Compounds also show activity against the human form of induced nitric oxide synthase as can be demonstrated in the following assay.
  • the human colorectal carcinoma cell line, DLD-1 obtained from the European Collection of Animal Cell Culture - cell line number 90102540
  • RPMI 1640 supplemented with 10%(v/v) foetal bovine serum, and 2mM L-glutamine, at 37 °C in 5% CO 2 .
  • Nitric oxide synthase was induced in cells by addition of medium containing human recombinant gamma-IFN (1000 units/ml), TNF-alpha (200 U/ml), IL-6 (200 U/ml) and IL-1-beta (250 U/ml). After incubation for 18 hours at 37 °C, the medium was removed and the cells washed with warm phosphate buffered saline. Cells were incubated for a further 5 hours at 37 °C / 5% CO 2 in RPMI 1640 containing 100 ⁇ M L-arginine and 100 ⁇ M verapamil-HCl in the presence and absence of test compounds.
  • Nitrite accumulation was determined by mixing an equal volume of culture media with Griess reagent (10 mg/ml sulphanilamide, 1 mg N-(1-naphthyl)ethylenediamine in 1 ml 2.5% (v/v) phosphoric acid). Inhibition in the presence of compounds was calculated relative to the nitrite levels produced by untreated cells. IC 50 values were estimated from a semi-log plot of % inhibition versus concentration of compound.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Claims (15)

  1. Composé de formule (I)
    Figure imgb0017
     dans laquelle :
    T et W représentent indépendamment CR1 ou N ; et lorsque plus d'un groupement R1 est présent, chacun peut être choisi indépendamment ;
    X et R1 représentent indépendamment H, alkyle en C1 à 4, alcoxy en C1 à 4, halogène, CN, C≡CH, NO2, CHO, COCH3 ou NHCHO ; ledit groupement alkyle ou alcoxy étant éventuellement en outre substitué par un ou plusieurs atomes de fluor ;
    Y représente alkyle en C1 à 4, alcoxy en C1 à 4, halogène, CN, C≡CH, NO2, CHO, COCH3 ou NHCHO ; ledit groupement alkyle ou alcoxy étant éventuellement en outre substitué par un ou plusieurs atomes de fluor ;
    ou un sel pharmaceutiquement acceptable de celui-ci.
  2. Composé selon la revendication 1, caractérisé en ce que Y représente CN ou halogène.
  3. Composé selon la revendication 1 ou 2, caractérisé en ce que X et R1 représentent indépendamment H, halogène ou CF3.
  4. Composé de formule (I), selon la revendication 1, caractérisé en ce qu'il s'agit de :
    2-[[(1R,3S)-3-amino-4-hydroxy-1-(5-thiazolyl)-butyl]thio]-5-chloro-3-pyridinecarbonitrile ;
    2-[[(1R,3S)-3-amino-4-hydroxy-1-(5-thiazolyl)-butyl]thio]-4-chlorobenzonitrile ;
    (2S,4R)-2-amino-4-[[2-chloro-5-(trifluorométhyl)-phényl]thio]-5-thiazolebutanol ;
    2-[[(1R,3S)-3-amino-4-hydroxy-1-(5-thiazolyl)-butyl]thio]-6-(trifluorométhyl)-3-pyridine-carbonitrile ;
    2-[[(1R,3S)-3-amino-4-hydroxy-1-(5-thiazolyl)-butyl]thio]-5-chlorobenzonitrile ;
    ou un sel pharmaceutiquement acceptable de celui-ci.
  5. Composé de formule (I), selon l'une quelconque des revendications 1 à 4, ou un sel pharmaceutiquement acceptable de celui-ci, destiné à être utilisé comme médicament.
  6. Composition pharmaceutique comprenant un composé de formule (I) selon l'une quelconque des revendications 1 à 4, ou un sel pharmaceutiquement acceptable de celui-ci, en mélange avec un adjuvant, un diluant ou un support pharmaceutiquement acceptable.
  7. Utilisation d'un composé de formule (I) selon l'une quelconque des revendications 1 à 4, ou d'un sel pharmaceutiquement acceptable de celui-ci, dans la fabrication d'un médicament destiné au traitement ou à la prophylaxie de maladies ou d'affections humaines dans lesquelles l'inhibition de l'activité de l'oxyde nitrique synthétase est bénéfique.
  8. Utilisation selon la revendication 7, caractérisée en ce qu'il s'agit majoritairement de l'oxyde nitrique synthétase inductible qui est inhibée.
  9. Utilisation d'un composé de formule (I) tel que défini dans les revendications 1 à 4, ou d'un sel pharmaceutiquement acceptable de celui-ci, dans la fabrication d'un médicament destiné au traitement ou à la prophylaxie de maladies inflammatoires.
  10. Utilisation selon la revendication 9, caractérisée en ce que la maladie est la maladie inflammatoire de l'intestin.
  11. Utilisation selon la revendication 9, caractérisée en ce que la maladie est la polyarthrite rhumatoïde.
  12. Utilisation selon la revendication 9, caractérisée en ce que la maladie est l'ostéoarthrite.
  13. Utilisation d'un composé de formule (I) tel que défini dans l'une quelconque des revendications 1 à 4, ou d'un sel pharmaceutiquement acceptable de celui-ci, dans la fabrication d'un médicament destiné au traitement ou à la prophylaxie des douleurs.
  14. Utilisation d'un composé de formule (I) tel que défini dans l'une quelconque des revendications 1 à 4, ou d'un sel pharmaceutiquement acceptable de celui-ci, en combinaison avec un inhibiteur de COX-2, dans la fabrication d'un médicament destiné au traitement ou à la prophylaxie de maladies inflammatoires.
  15. Procédé de préparation d'un composé de formule (I), tel que défini dans l'une quelconque des revendications 1 à 4, ou d'un sel, d'un énantiomère ou d'un racémate pharmaceutiquement acceptable de celui-ci, caractérisé en ce que le procédé comprend :
    (a) la réaction d'un composé de formule (II)
    Figure imgb0018
     dans laquelle T, X, Y et W sont tels que définis dans la revendication 1 et L1 représente un groupement partant,
    avec un composé de formule (III)
    Figure imgb0019
     ou
    (b) la réaction d'un composé de formule (IV)
    Figure imgb0020
     dans laquelle T, W, X et Y sont tels que définis dans la revendication 1,
    avec un composé de formule (V)
    Figure imgb0021
     dans laquelle L2 est un groupement partant ;
    et, si on le souhaite ou s'il est nécessaire, la transformation du composé de formule (I) résultant, ou d'un autre sel de celui-ci, en un sel pharmaceutiquement acceptable de celui-ci ; ou la transformation d'un composé de formule (I) en un autre composé de formule (I) ; et, si on le souhaite, la transformation du composé résultant de formule (I) en un isomère optique de celui-ci.
EP03770201A 2002-11-07 2003-11-06 3-arylthio-3-thiazolyl-alkylamines anti-inflammatoires Expired - Lifetime EP1562920B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0203304 2002-11-07
SE0203304A SE0203304D0 (sv) 2002-11-07 2002-11-07 Novel Coumpounds
PCT/SE2003/001712 WO2004041794A1 (fr) 2002-11-07 2003-11-06 3-arylthio-3-thiazolyl-alkylamines anti-inflammatoires

Publications (2)

Publication Number Publication Date
EP1562920A1 EP1562920A1 (fr) 2005-08-17
EP1562920B1 true EP1562920B1 (fr) 2006-06-28

Family

ID=20289508

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03770201A Expired - Lifetime EP1562920B1 (fr) 2002-11-07 2003-11-06 3-arylthio-3-thiazolyl-alkylamines anti-inflammatoires

Country Status (9)

Country Link
US (1) US20060040992A1 (fr)
EP (1) EP1562920B1 (fr)
JP (1) JP2006506414A (fr)
AT (1) ATE331711T1 (fr)
AU (1) AU2003278667A1 (fr)
DE (1) DE60306546T2 (fr)
ES (1) ES2268441T3 (fr)
SE (1) SE0203304D0 (fr)
WO (1) WO2004041794A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR035700A1 (es) * 2001-05-08 2004-06-23 Astrazeneca Ab Derivados de arilheteroalquilamina, composicion farmaceutica, usos de estos derivados para la fabricacion de medicamentos, metodos de tratamiento, y proceso para la preparacion de estos derivados
WO2009050248A1 (fr) 2007-10-19 2009-04-23 Boehringer Ingelheim International Gmbh Pipéridino-dihydrothiénopyrimidines substituées
EA020548B1 (ru) 2008-12-19 2014-12-30 Бёрингер Ингельхайм Интернациональ Гмбх Циклические пиримидин-4-карбоксамиды в качестве антагонистов рецептора ccr2, предназначенные для лечения воспаления, астмы и хозл
JP5658272B2 (ja) 2009-12-17 2015-01-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ２の新規アンタゴニスト及びこれらの使用
MX2012006964A (es) 2009-12-17 2012-07-17 Boehringer Ingelheim Int Nuevos antagonistas del receptor ccr2 y usos de los mismos.
CA2786245A1 (fr) 2010-01-29 2011-08-04 Boehringer Ingelheim International Gmbh Naphtyridines substituees et leur utilisation comme inhibiteurs de syk kinase
JP2013526507A (ja) 2010-05-12 2013-06-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規ｃｃｒ２受容体アンタゴニスト、その製造方法及び薬物としてのその使用
WO2011141477A1 (fr) 2010-05-12 2011-11-17 Boehringer Ingelheim International Gmbh Nouveaux antagonistes du récepteur ccr2, leur procédé de production et leur utilisation en tant que médicaments
US8841313B2 (en) 2010-05-17 2014-09-23 Boehringer Ingelheim International Gmbh CCR2 antagonists and uses thereof
EP2576542B1 (fr) 2010-05-25 2015-04-22 Boehringer Ingelheim International GmbH Dérivés d'amide cycliques d'acides pyridazine-3-carboxyliques utiles dans le traitement de maladies respiratoires, liées à des douleurs, liées au système immunitaire et cardiovasculaires
US8962656B2 (en) 2010-06-01 2015-02-24 Boehringer Ingelheim International Gmbh CCR2 antagonists
JP5959537B2 (ja) 2011-01-28 2016-08-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換ピリジニル−ピリミジン及び医薬としてのその使用
JP5786257B2 (ja) 2011-06-16 2015-09-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規の選択的ｃｃｒ２拮抗薬
JP5786258B2 (ja) 2011-07-15 2015-09-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規かつ選択的なｃｃｒ２拮抗薬
EP2736886B1 (fr) 2011-07-26 2016-09-14 Boehringer Ingelheim International GmbH Quinolines substitués et leur utilisation en tant que médicaments
US20130059866A1 (en) 2011-08-24 2013-03-07 Boehringer Ingelheim International Gmbh Novel piperidino-dihydrothienopyrimidine sulfoxides and their use for treating copd and asthma
US9096579B2 (en) 2012-04-20 2015-08-04 Boehringer Ingelheim International Gmbh Amino-indolyl-substituted imidazolyl-pyrimidines and their use as medicaments
ES2738416T3 (es) 2014-03-19 2020-01-22 Boehringer Ingelheim Int Inhibidores heteroarílicos de SYK
GB201512635D0 (en) 2015-07-17 2015-08-26 Ucl Business Plc Uses of therapeutic compounds

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2688638A (en) * 1951-07-17 1954-09-07 Givaudan Corp Nu-(beta-phenoxyethyl) haloethylamines
US4314081A (en) * 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
FR2432500A1 (fr) * 1978-02-24 1980-02-29 Roussel Uclaf Nouveaux derives de la benzene propanamine et leurs sels, procede de preparation et application a titre de medicaments
US4325953A (en) * 1979-09-14 1982-04-20 John Wyeth And Brother Limited 4-Aryl-4-aryloxypiperidines
DE3138550A1 (de) * 1981-09-28 1983-04-07 Boehringer Ingelheim KG, 6507 Ingelheim Substituierte 2-phenyl-2-(pyridyloxy)-ethylamine und isostere verbindungen, verfahren zu ihrer herstellung und verwendung
DE3328348A1 (de) * 1983-08-05 1985-02-14 Degussa Ag, 6000 Frankfurt Verfahren zur duennschichtchromatographischen trennung von enantiomeren
US4902710A (en) * 1988-12-14 1990-02-20 Eli Lilly And Company Serotonin and norepinephrine uptake inhibitors
GB0004149D0 (en) * 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel compounds
GB0004151D0 (en) * 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel use
GB0004153D0 (en) * 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel use
GB0004152D0 (en) * 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel compounds
AR035700A1 (es) * 2001-05-08 2004-06-23 Astrazeneca Ab Derivados de arilheteroalquilamina, composicion farmaceutica, usos de estos derivados para la fabricacion de medicamentos, metodos de tratamiento, y proceso para la preparacion de estos derivados
SE0102641D0 (sv) * 2001-07-31 2001-07-31 Astrazeneca Ab Novel compounds
SE0102640D0 (sv) * 2001-07-31 2001-07-31 Astrazeneca Ab Novel compounds
US7084122B2 (en) * 2001-11-21 2006-08-01 Erik Larsen Use of glycosides of mono- and diacyglycerol as anti-inflammatory agents

Also Published As

Publication number Publication date
WO2004041794A8 (fr) 2005-03-10
DE60306546D1 (de) 2006-08-10
SE0203304D0 (sv) 2002-11-07
WO2004041794A1 (fr) 2004-05-21
DE60306546T2 (de) 2007-07-05
ES2268441T3 (es) 2007-03-16
US20060040992A1 (en) 2006-02-23
EP1562920A1 (fr) 2005-08-17
ATE331711T1 (de) 2006-07-15
JP2006506414A (ja) 2006-02-23
AU2003278667A1 (en) 2004-06-07

Similar Documents

Publication Publication Date Title
EP1562920B1 (fr) 3-arylthio-3-thiazolyl-alkylamines anti-inflammatoires
US20040242871A1 (en) Novel arylheteroalkylamine derivatives
WO2000021934A1 (fr) Composes
WO2002012187A1 (fr) Nouvelles phenylheteroazetidines utiles comme inhibiteurs de la synthase d'oxyde nitrique
US7119109B2 (en) Heteroarylheteroalkylamine derivatives and their use as inhibitors of nitric oxide synthase
EP1414802B1 (fr) Derives d'heteroarylheteroalkylamine, et leur utilisation comme inhibiteurs de la synthase du monoxyde d'azote
EP1263715B1 (fr) Nouveaux derives de phenylheteroalkylamine
US7223794B2 (en) Arylheteroalkylamine derivatives and their use as inhibitors of nitric oxide synthase
US7329686B2 (en) Substituted thiophene compounds
EP1263718B1 (fr) Nouvelle utilisation de derives de phenylheteroalkylamine
EP1539731B1 (fr) Nouveaux composes
US20060194847A1 (en) Novel 6-substituted 2-aminopyridine derivatives
US20060270714A1 (en) Novel n-substituted 2-aminopyridine derivatives

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050607

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

DAX Request for extension of the european patent (deleted)
GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060628

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED.

Effective date: 20060628

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060628

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060628

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060628

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060628

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060628

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060628

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060628

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 60306546

Country of ref document: DE

Date of ref document: 20060810

Kind code of ref document: P

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060928

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20061106

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20061128

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20061130

NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
ET Fr: translation filed
REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2268441

Country of ref document: ES

Kind code of ref document: T3

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20070329

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060929

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060928

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060628

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060628

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20061229

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20061106

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060628

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20081028

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20081118

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20081125

Year of fee payment: 6

Ref country code: SE

Payment date: 20081107

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20081106

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20081128

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20081008

Year of fee payment: 6

EUG Se: european patent has lapsed
REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20091106

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20100730

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20091130

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20091130

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20091130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100601

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20091106

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20110302

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20091106

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20091107

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110301

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20091107